Archived explainer. For the current picture see today's AGEN page.
AGENUS INC EQUITY Equity (AGEN) is drawing unusual attention today. Our newswire has captured 11 stories on AGEN across 8 sources in the last 36 hours, with AI sentiment reading mixed (avg 47/100).
Agenus Inc (NASDAQ:AGEN) shares surged approximately 100% on Monday as the biotechnology company announced an oversubscribed private placement of up to $340 million to support its ROBBIN Phase 3 trial for the BOT+BAL combination in microsatellite stable (MSS) colon cancer. The funding is expected to provide an initial $85 million with the potential for an additional $255 million, signaling strong investor confidence in the company's neoadjuvant immunotherapy strategy. This development has positioned AGEN as a focal point in the healthcare sector.
According to Yahoo Finance, Agenus shares jumped about 100% after the company announced the private placement, which will support the development of its botensilimab and balsilimab therapies. TipRanks reported that the stock's rise was accompanied by a price target increase, while MarketChameleon described the financing as a "landmark deal" targeting a $7 billion market with no new curative therapies in a decade. InvestorsHub noted that the financing package will extend the company's cash runway and support its Phase 3 clinical program. The financing was structured with premium warrant pricing, highlighting investor confidence, according to MarketChameleon.
AGEN's unusual options activity in the last 36 hours shows 9 notable prints, with a call premium of $1.3 million versus a put premium of $1.0 million. The largest single print was $789K. The stock's market cap is $139.5M, with a P/E of 1.7 and a beta of 1.55. Revenue has grown 24.5% in the trailing twelve months, and the stock is currently trading within its 52-week range of $2.71 to $7.34.
Agenus is not scheduled to release earnings in the near term. Investors should monitor the breadth of coverage and sentiment surrounding the ROBBIN trial, as well as any further developments in the financing structure or regulatory updates.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
Agenus Inc. (AGEN) Discusses Financing and Robin Trial Strategy for Neoadjuvant Immunotherapy in MSS Colon Cancer July 13, 2026 8:30 AM EDTCompany...
Agenus expects to receive about $85 million soon under a placement, with the potential for another $255 million later.
Agenus (Agenus Inc (NASDAQ:AGEN)) shares jumped about 100% on Monday after the biotechnology company announced an oversubscribed private placement of up to $340 million to support development of its botensilimab and balstilimab (BOT+BAL) immunotherapy combination in microsatellite-stable (MSS)...
Agenus stock was up on Monday alongside a new funding announcement and a price target increase.
Agenus announces a landmark financing deal of up to $340 million to advance its ROBBIN Phase 3 trial for the BOT+BAL combination in MSS colon cancer, targeting a $7 billion market with no new curative therapies in decades.
Agenus shares rose after the company announced an $85 million private placement, with total potential financing of up to $340 million to support its Phase 3 clinical programme and extend its cash runway.
The latest announcement is out from Agenus ( ($AGEN) ). On July 13, 2026, Agenus agreed to a private placement with institutional and accredited investors, raising ...
Agenus has locked in up to $340 million through an oversubscribed private placement, targeting its pivotal Phase 3 ROBBIN trial for neoadjuvant BOT+BAL in MSS colon cancer. Notably, the financing was structured at a premium to market and features significant investor participation, supporting Agenus' focus on a $7 billion annual U.S. sales opportunity.
More on AGEN: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier AGEN move explainers: 2026-07-13